| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/08/2011 | US20110218182 Chemical compounds 251 |
| 09/08/2011 | US20110218176 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| 09/08/2011 | US20110218174 Novel cyclic benzimidazole derivatives useful as anti-diabetic agents |
| 09/08/2011 | US20110218171 Trehalose compound, method for producing same, and pharmaceutical product containing the compound |
| 09/08/2011 | US20110218170 Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents |
| 09/08/2011 | US20110218167 Triterpenoid 2-deoxy Glycosides, Method of Preparation Thereof and Use Thereof as Medicaments |
| 09/08/2011 | US20110218155 Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| 09/08/2011 | US20110218154 Histone deacetylases, and uses related thereto |
| 09/08/2011 | US20110218150 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 09/08/2011 | US20110218147 Activin-actriia antagonists for inhibiting germ cell maturation |
| 09/08/2011 | US20110218138 Pharmaceutical composition containing polypeptide fragments of serralysins |
| 09/08/2011 | US20110217394 Iridoid Based Formulations |
| 09/08/2011 | US20110217379 Magnetic nanomaterials and methods for chemoembolisation |
| 09/08/2011 | US20110217377 Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| 09/08/2011 | US20110217376 Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same |
| 09/08/2011 | US20110217367 Means for inhibiting the expression of orc-1 |
| 09/08/2011 | US20110217364 Conjugated suramin amino compounds for medical conditions |
| 09/08/2011 | US20110217363 Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier |
| 09/08/2011 | US20110217354 Implants for administering substances and methods of producing implants |
| 09/08/2011 | US20110217335 Synthesis of resorcylic acid lactones useful as therapeutic agents |
| 09/08/2011 | US20110217326 Method for diagnosing and/or treating tumor |
| 09/08/2011 | US20110217323 Imidazoquinoline compounds |
| 09/08/2011 | US20110217321 Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
| 09/08/2011 | US20110217319 Methods of use of sialoadhesin factor-2 antibodies |
| 09/08/2011 | US20110217316 GBS Toxin Receptor Compositions and Methods of Use |
| 09/08/2011 | US20110217314 Methods and Compositions for Modulating Apoptosis |
| 09/08/2011 | US20110217309 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| 09/08/2011 | US20110217306 C-terminal exon 5.4 of runx1/aml1 |
| 09/08/2011 | US20110217305 Anti-her2 antibodies and compositions |
| 09/08/2011 | US20110217304 Monoclonal antibodies directed to cd52 |
| 09/08/2011 | US20110217300 Quinazolinone Compounds and Methods of Use Thereof |
| 09/08/2011 | US20110217299 Targeting pax2 for the treatment of breast cancer |
| 09/08/2011 | US20110217298 Monoclonal antibodies directed to cd20 |
| 09/08/2011 | US20110217297 Methods for classifying and treating breast cancers |
| 09/08/2011 | US20110217296 Method for selecting patients for treatment with an egfr inhibitor |
| 09/08/2011 | US20110217294 Combination of hgf inhibitor and hedgehog inhibitor to treat cancer |
| 09/08/2011 | US20110217282 Novel Toxin-Antitoxin System |
| 09/08/2011 | US20110217281 Methods for diagnosis and prognosis of cancer |
| 09/08/2011 | US20110217279 Use of human biliverdin reductase and fragments thereof for the treatment of protein kinase c-delta and erk related conditions |
| 09/08/2011 | US20110217270 Methods for treating tumors and cancerous tissues |
| 09/08/2011 | US20110217267 Gene therapy vectors and cytosine deaminases |
| 09/08/2011 | US20110217266 Genomic sequence of avian paramyxovirus type 2 and uses thereof |
| 09/08/2011 | US20110217263 Expansion of haemopoietic precursors |
| 09/08/2011 | US20110217258 Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma |
| 09/08/2011 | US20110217249 Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds |
| 09/08/2011 | US20110217239 System and method of evaluating a protein of interest on tumor growth inhibition while following the tumor in vivo or in vitro |
| 09/08/2011 | US20110217237 Therapeutic dll4 binding proteins |
| 09/08/2011 | US20110217236 Radiation sensitive liposomes |
| 09/08/2011 | US20110217231 Anti-tenascin monoclonal antibody therapy for lymphoma |
| 09/07/2011 | EP2363487A2 A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
| 09/07/2011 | EP2363479A1 Oligoribonucucleotide for inhibiting the expression of a predefined gene |
| 09/07/2011 | EP2363478A1 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 09/07/2011 | EP2363468A1 Tumor antigen peptide and use thereof |
| 09/07/2011 | EP2363410A1 Isoforms of MUC1 |
| 09/07/2011 | EP2363404A2 PSMA antibodies |
| 09/07/2011 | EP2363403A2 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 09/07/2011 | EP2363401A1 Ibandronate polymorph B |
| 09/07/2011 | EP2363393A1 Compounds and compositions as hedgehog pathway modulators |
| 09/07/2011 | EP2363146A1 Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis |
| 09/07/2011 | EP2363139A1 Method to increase class I presentation of exogenous antigens by human dendritic cells |
| 09/07/2011 | EP2363138A1 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring periodontal diseases |
| 09/07/2011 | EP2363136A1 Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
| 09/07/2011 | EP2363133A1 Composition comprising DNA fragments and medical and cosmetic uses thereof |
| 09/07/2011 | EP2363129A1 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| 09/07/2011 | EP2362906A1 Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| 09/07/2011 | EP2362905A1 Screening method of anti-lung or esophageal cancer compounds |
| 09/07/2011 | EP2362904A1 Method for treating or preventing bladder cancer using the depdc1 polypeptide |
| 09/07/2011 | EP2362873A2 New crystal form of sunitinib malate |
| 09/07/2011 | EP2362872A2 Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors |
| 09/07/2011 | EP2362783A2 Light targeting molecules and uses thereof |
| 09/07/2011 | EP2362773A1 Methods for inducing programmed cell death |
| 09/07/2011 | EP2362772A1 Pharmaceutical association lipoic acid and hydroxycitric acid as active ingredients |
| 09/07/2011 | EP2362767A2 Formulations of single domain antigen binding molecules |
| 09/07/2011 | EP2215085B1 Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| 09/07/2011 | EP2181104B1 Zearalenone macrolide derivatives and uses of the same |
| 09/07/2011 | EP2101790B1 Combination comprising sapacitibine (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 09/07/2011 | EP2100605B1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer |
| 09/07/2011 | EP2065388B1 Pyrazolopyrimidine derivative |
| 09/07/2011 | EP2049500B1 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| 09/07/2011 | EP2046737B1 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
| 09/07/2011 | EP1996625B1 Anti-tat226 antibodies and immunoconjugates |
| 09/07/2011 | EP1877383B1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity |
| 09/07/2011 | EP1850851B1 Pyrrolo[2,3-d]pyrimidines for treating cancer by inhibiting mitosis |
| 09/07/2011 | EP1239862B3 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating tumor diseases |
| 09/07/2011 | CN1990475B Substituted benzisoselenazolone compounds and use thereof |
| 09/07/2011 | CN1970034B Chinese medicine containing gadol and tuckahoe |
| 09/07/2011 | CN1840204B Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 09/07/2011 | CN1814153B Medicine composition for preventing and treating breast cancer and preparing method |
| 09/07/2011 | CN1582150B Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| 09/07/2011 | CN102177178A Anti-IL-12/IL-23 antibodies |
| 09/07/2011 | CN102177159A Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 09/07/2011 | CN102177153A Compositions and methods for treating alcohol use disorders, pain and other diseases |
| 09/07/2011 | CN102177152A Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| 09/07/2011 | CN102177144A Crystalline forms of (R) -5- [3-chloro-4- ( 2, 3-dihydroxy-propoxy) -benz [Z] ylidene] -2- ( [Z] -propylimino) -3-0-tolyl-thiazolidin-4-one |
| 09/07/2011 | CN102176922A Pharmaceutical compositions comprising antibodies binding to EBV (Epstein-Barr virus) protein BARF1 |
| 09/07/2011 | CN102176919A Methods and compositions for treatment of bone defects with placental cell populations |
| 09/07/2011 | CN102176914A VHZ for diagnosis and treatment of cancers |
| 09/07/2011 | CN102176900A Pharmaceutical compositions and related methods of delivery |
| 09/07/2011 | CN102174623A Fermentation method and application of yeast engineering bacteria |
| 09/07/2011 | CN102174615A Method for producing fungal polysaccharide with residues after extraction of polysaccharide using needle mushroom |